Sullivan Mark 4
4 · Definium Therapeutics, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Definium (DFTX) CLO Mark Sullivan Sells 10,702 Shares
What Happened
Mark Sullivan, Chief Legal Officer of Definium Therapeutics (DFTX), sold 10,702 common shares on March 25, 2026 in open-market/private transactions (reported as “S”). The weighted-average sale price was $18.47, for total proceeds of approximately $197,666. The filing indicates the sales were sell-to-cover transactions to satisfy withholding tax on vested restricted stock units.
Key Details
- Transaction date: March 25, 2026; Form 4 filed March 26, 2026 (timely).
- Shares sold: 10,702; weighted-average price: $18.47; total proceeds: ~$197,666.
- Price range: $18.36 to $18.80 across multiple trades (filing provides weighted avg and range; per-trade breakdown available on request) (F2).
- Reason: Sell-to-cover to satisfy withholding tax on vested RSUs, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted March 14, 2024 (F1).
- Ownership after transaction: Not specified in the filing.
- Additional note: Filing states an amount includes 793 shares acquired under the 2024 Employee Share Purchase Plan (ESPP) (F3).
Context
These sales were routine sell-to-cover transactions tied to RSU vesting and a pre-established 10b5-1 plan, which are commonly used to satisfy tax obligations and do not necessarily signal a change in the insider’s view of the company. Purchases generally carry more weight as signals; this sale appears administrative in nature.
Insider Transaction Report
- Sale
Common Shares
[F1][F2][F3]2026-03-25$18.47/sh−10,702$197,666→ 271,079 total
Footnotes (3)
- [F1]Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024.
- [F2]The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Amount includes 793 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan.